Third Rock startup grabs $60M to crack the cellular code of disease

“Cells are like people,” Rheos Medicines co-founder Larry Turka says, explaining the science behind the new Cambridge biotech startup. “They behave differently depending on how they get their energy, just like how you or I feel differently depending on whether we had pizza or salad for lunch.” Rheos, which officially launched on Thursday with $60 million in financing from Third Rock Ventures, is aiming to develop drugs that tweak what scientists call “metabolic pathways” — the complex…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news